Improving Breast Cancer Treatment with Personalized Approaches
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes
This program helps women with high-risk, early breast cancer find the best personalized treatments by adjusting therapy based on how their body responds.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11125942 on NIH RePORTER |
What this research studies
This program focuses on women with stage 2 and 3 early breast cancer who have a high risk of their cancer progressing quickly. We are developing a patient-centered way to find the most effective treatments for each individual. This involves adjusting therapies, either increasing or decreasing them, based on how a patient's body responds to treatment, using imaging and molecular markers. The goal is to discover new first-line treatments and improve outcomes for these patients. The insights gained from this work could also help with other types of cancer.
Who could benefit from this research
Good fit: Ideal candidates are women with stage 2 or 3 early breast cancer that is considered molecularly high-risk.
Not a fit: Patients with very early-stage or metastatic breast cancer, or those not considered high-risk, may not directly benefit from this specific program.
Why it matters
Potential benefit: If successful, this program could lead to more complete responses to treatment and help prevent breast cancer from spreading.
How similar studies have performed: The I-SPY program has an established history of continuous improvement in clinical trial design and personalized treatment strategies.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Esserman, Laura J — University of California, San Francisco
- Study coordinator: Esserman, Laura J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.